CYCN

Cyclerion Therapeutics, Inc.

2.45 USD

Last updated Dec 11, 23:20 UTC

Yesterday HIGH

$2.54

Yesterday LOW

$2.41

52w HIGH

$19.14

52w LOW

$1.75

EPS

-2.12

PE

-1.16

Next Earnings

Mar 20, 2024

Overview News Insider Transactions Government Trades

Cyclerion Therapeutics, Inc. stock is up 11.87% since 30 days ago. The next earnings date is Mar 20, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 40% of the previous 4 December’s closed higher than November.

Cyclerion Therapeutics, Inc. engages in the discovering, development, and commercialization of medicines for serious central nervous system (CNS) diseases. Its lead product candidate is CY6463, a CNS-penetrant, soluble guanylate cyclase (sGC) stimulator that is in Phase IIa trials for the treatment of mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes, as well as Alzheimer's disease with vascular pathology. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.

Stock Exchange

NASDAQ

Sector

Manufacturing

Industry

Pharmaceutical Products

Headquarters

-

Website

cyclerion.com

Happy Mohamed

Thu Mar 23, 2023

Cyclerion Therapeutics Gets FDA Orphan Drug Designation For Zagociguat For Treatment Of Mitochondrial Disease

https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=931423
Happy Mohamed

Wed Mar 22, 2023

Cyclerion Reports Corporate Update And FY22 Financial Results; Cash, Cash Equivalents, And Restricted Cash Balance On December 31, 2022 Was ~$13.4M

Cyclerion Therapeutics, Inc. (NASDAQ:CYCN) today announced corporate updates including advances in its zagociguat (formerly CY6463) mitochondrial disease program. The Company previously reported clinical data in
Benzinga Newsdesk

Thu Feb 2, 2023

Cyclerion Therapeutics Receives Notice Of Allowance For Patent Application Titled "NOVEL PROCESSES AND INTERMEDIATES FOR THE PREPARATION OF SOLUBLE GUANYLATE CYCLASE STIMULATORS".

https://patentcenter.uspto.gov/applications/17497352/ifw/docs
Lisa Levin

Wed Nov 23, 2022

Why American Eagle Outfitters Shares Climbed Over 18%; Here Are 78 Biggest Movers From Yesterday

Gainers Cosmos Holdings Inc. (NASDAQ: COSM) jumped 86.9% to close at $0.3275 on Tuesday after jumping 21% on Monday. Cosmos Health agreed to sell its Sky Premium Life Luxury food supplement brand on Iberian Airlines' in-flight magazine, Ronda.
Lisa Levin

Tue Nov 22, 2022

Why Dollar Tree Shares Are Trading Lower By 10%? Here Are 53 Stocks Moving In Tuesday's Mid-Day Session

Gainers Palisade Bio, Inc. (NASDAQ: PALI) shares jumped 99.1% to $4.42 after the company announced the FDA granted Fast Track designation to LB1148 for the acceleration of time to return of bowel function following surgery.
Benzinga Insights

Tue Nov 22, 2022

12 Health Care Stocks Moving In Tuesday's Intraday Session
Benzinga Insights

Tue Nov 22, 2022

12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Bill Haddad

Tue Nov 22, 2022

Cyclerion Says Concluded The Unsolicited Proposal Received On Nov. 20 Was 'Not in The Best Interest of The Company'

Cyclerion Therapeutics, Inc. (NASDAQ:CYCN) today announced that the Board of Directors of the Company acting solely by all of its independent and disinterested members (the "Independent Board") has reviewed the
Lisa Levin

Tue Nov 22, 2022

Why ObsEva Shares Are Trading Higher By Over 70%; Here Are 21 Stocks Moving Premarket

Gainers ObsEva SA (NASDAQ: OBSV) shares rose 71.9% to $0.2848 in pre-market trading after the company reported the sale of Ebopiprant license agreement to XOMA for up to $113 million.
Lisa Levin

Fri Oct 28, 2022

Why Meta Platforms Shares Dipped Around 25%; Here Are 77 Biggest Movers From Yesterday

Gainers UserTesting, Inc. (NYSE: USER) shares jumped 91.7% to close at $7.40 after the company announced it will be acquired by Thoma Bravo and Sunstone Partners for $1.3 billion. The company also reported better-than-expected Q3 sales results.

MCGUIRE TERRANCE, Director

Thu Nov 30, 2023

CYCN Recent Insider Trades and Stock Chart

5,000 shares awarded
Hecht Peter M, Director

Thu Nov 30, 2023

CYCN Recent Insider Trades and Stock Chart

20,000 shares awarded
DESOUZA ERROL B, Director

Thu Nov 30, 2023

CYCN Recent Insider Trades and Stock Chart

50,000 shares awarded
Hyman Steven, Director

Thu Nov 30, 2023

CYCN Recent Insider Trades and Stock Chart

20,000 shares awarded
Hecht Peter M, Director

Fri Dec 1, 2023

CYCN Recent Insider Trades and Stock Chart

15,000 shares awarded